Akums Drugs And Pharmaceuticals Limited · NSE:AKUMS
Akums Drugs And Pharmaceuticals — Q1 FY26 Earnings Presentation
15 slides from Akums Drugs And Pharmaceuticals's earnings presentation, Aug 8, 2025
Slide 1: Exchange filing cover letter under Regulation 30
Ref: Akums/Exchange/2025-26/34 August 08, 2025 To, To, The Listing Department The Listing Department National Stock Exchange of India Ltd BSE Limited Exchange Plaza, C-1, Block G, Rotunda Building, Phiroze Jeejeebhoy Bandra Kurla Complex, Towers, Dalal Street, Fort, Mumbai – Bandra (E),Mumbai – 400
Slide 2: Earnings Presentation August 2025
Earnings Presentation August 2025
Slide 3: Disclaimer
Disclaimer Akums Drugs and Pharmaceuticals Limited may, from time to time, make written and oral forward-looking statements, in addition to statements contained in the company's filings with BSE Limited (BSE) and National Stock Exchange of India Limited (NSE), and its reports to shareholders. The co
Slide 4: Managing Directors' Message
Managing Directors’ Message Dear Investors We are pleased to declare the Q1 results for FY 26. This date marks just over one year since we began our journey as a listed company. We continue to work towards strengthening the organization with a focus on long term growth. The long-term growth prospect
Slide 5: Two Decades' Legacy of Expertise, Experience & Trust
Two Decades’ Legacy of Expertise, Experience & Trust Dedicated facilities for Expanded into Asian markets. Hormones, Cosmetics Established dedicated and Dermatology. Quadria Capital Established R&D lab in Mumbai to manufacturing site for bought a minority Launched Akumentis to venture into regulated
Slide 6: Technologically Advanced Manufacturing Capabilities
Technologically Advanced Manufacturing Capabilities Location Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Kotdwar Baddi Haridwar Year 2004 2007 2007 2010 2010 2010 2014 2014 2021 2023 2024 Annual Capacity (Cr units) 649 15 39 244 6 252 2.603 732 17 368 36 Ayurvedic / β-lac
Slide 7: R&D Focus
R&D Focus Illustrative Tablet Bi-layered, Inlay Multiple Tablets Pre-filled In Tablet Sustained Release Tablet in Capsule syringes Tablet in Tablet Lyophilized Smart Gummies Mouth Melting Tri Layered Vials Tablets Powders in Sachet Tablet Innovative In-house Technologies (1) As of 31st March 2025 6
Slide 8: Key Highlights
Key Highlights 1,518 Cr. 1,000 € 100 Mn Zero Liquid Cash Surplus DGCI Approvals Received as advance Discharge (ZLD) (566 Cr in FY25) (+27 in Q1FY26) against European implemented across CDMO contract 5 plants Brazil ANVISA 20 New Approvals 44 Dossiers filed – 1st Strengthened senior approval for Plan
Slide 9: Financial Performance Highlights
Q1 FY 26 Financial Performance Highlights 8
Slide 10: Consolidated Performance Highlights
Consolidated Performance Highlights Q1 FY26 Segment Break-up Share in Q1 FY26 Business Vertical revenue 156 cr 65 cr CDMO 79.4% 1,051 cr 14.8% 6.2% Domestic Branded 10.5% Formulation Total Income Adj. EBITDA Adj. PAT API 4.4% (+2.4% YoY) (+208 bps YoY) (+57 bps YoY) International Branded 3.4% Formul
Slide 11: Consolidated Quarterly Performance Highlights
Consolidated Quarterly Performance Highlights Total Income (INR Cr.) Adjusted EBITDA1 (INR Cr) Adjusted PAT2 (INR Cr) Margin % Margin % 12.7% 12.9% 13.3% 10.4% 14.8% 5.6% 6.4% 6.5% 4.1% 6.2% 2.4% 19.1% 12.8 % 1,073 156 1,026 1,047 1,025 1,051 67 66 65 131 135 136 57 111 44 Q1 FY 25 Q2 FY 25 Q3 FY 25
Slide 12: Revenue and Margin Breakdown
Revenue and Margin Breakdown Total Income (INR Cr.) Adj EBIDTA % CDMO Revenue (INR Cr.) 6.6% • CDMO growth slow on account of declining • Improved gross margins driven by continued • Despite dip in API prices as well as muted API prices and muted volume growth focus on niche products. volume growth,
Slide 13: Segmental Quarterly Performance
Segmental Quarterly Performance Domestic Branded International Branded Trade CDMO Revenue API Revenue Formulation Revenue Formulation Revenue generics Revenue QoQ -3.1% YoY 4.0% QoQ 3.7% YoY 3.4% QoQ -11.7% YoY 2.4% QoQ 3.8% YoY -20.9% QoQ -10.2% YoY -35.4% 840 813 40 70 782 107 35 29 104 104 34 22
Slide 14: Objects of the offer
Objects of the offer Amount as per offer Utilization as on June Objects (INR Cr) Unutilized Amount document 30, 2025 Repayment borrowings of Akums 159.91 159.91 - Repayment of borrowings of our 227.09 227.09 - Subsidiaries Funding incremental working capital 55.00 55.00 - requirements of our Company
Slide 15: Thank You
Thank You For further information, contact: IR Desk Akums Drugs and Pharmaceuticals Ltd Email: investors@akums.net/ankit.jain@akums.net Siddharth Rangnekar / Shruti Joshi CDR, India Tel: +91 97699 19966 / 75065 67349 Email: siddharth@cdr-india.com / shruti@cdr-india.com 14
Akums Drugs and Pharmaceuticals — Q1 FY26 Earnings Presentation on 6ix